Moreover, detection of BRAF (V600E) mutations have been suggested to be helpful to distinguish PXA from diffuse astrocytic tumors WHO grade II, III and IV elsewhere[28]. The gene discussed is BRAF; the disease is pleomorphic xanthoastrocytoma.